Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses

Vaccine

Volumn 20, Issue 11-12, 2002, Pages 1609-1617

  Balasuriya, Udeni B R ^a   Heidner, Hans W ^b   Davis, Nancy L ^c   Wagner, Heike M ^a   Hullinger, Pamela J ^d   Hedges, Jodi F ^a   Williams, Jacqueline C ^b   Johnston, Robert E ^c   David Wilson, W ^a   Liu, Irwin K ^a   James MacLachlan, N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d CALIFORNIA DEPARTMENT OF FOOD AND AGRICULTURE   (United States)

Author keywords

EAV; Vaccination; VEE

Indexed keywords

NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN GL; VIRUS ENVELOPE PROTEIN M;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EQUINE VIRAL ARTERITIS VIRUS; FEMALE; HAMSTER; HORSE; HORSE DISEASE; IMMUNIZATION; IMMUNOGENICITY; KIDNEY CELL; MALE; NONHUMAN; NOSE SECRETION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; VACCINATION; VIRUS NEUTRALIZATION; VIRUS SHEDDING; VIRUS STRAIN;

ANIMALS; ARTERITIS VIRUS, EQUINE; ARTERIVIRUS INFECTIONS; CATTLE; CELL LINE; CRICETINAE; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FEMALE; GENETIC VECTORS; HORSE DISEASES; HORSES; MALE; REPLICON; VACCINATION; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRULENCE;

EID: 0037154783     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00485-6     Document Type: Article

References (50)

1. Serologic and molecular characterization of an abortigenic strain of equine arteritis virus derived from infective frozen semen and an aborted equine fetus
2. Genetic stability of equine arteritis virus during horizontal and vertical transmission in an outbreak of equine viral arteritis
3. Expression of two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles
4. L) of equine arteritis virus
5. L envelope glycoprotein
6. A 29K envelope glycoprotein of equine arteritis virus expresses neutralization determinants recognized by murine monoclonal antibodies
7. Equine arteritis virus derived from an infectious cDNA clone is attenuated and genetically stable in infected stallions
8. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector
9. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
10. Nidovirales: A new order comprising Coronaviridae and Arteriviridae
11. Mucosal immunity induced by parental immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate
12. L
13. Transmissibility and abortogenic effect of equine viral arteritis in mares
14. Attenuated mutations of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutations in E1
15. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge
16. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
17. Structural proteins of equine arteritis virus
18. The two major envelope proteins of equine arteritis virus associate into disulfide-linked heterodimers
19. Equine arteritis virus is not a togavirus but belongs to the coronavirus like superfamily
20. L protein as a target for virus neutralization
21. Isolation of a filterable agent causing arteritis of horses
22. An outbreak of abortion caused by the equine arteritis virus
23. Complement-dependent serum neutralization with virulent and avirulent Bucyrus strains of equine arteritis virus
24. Use of the serum neutralisation test for equine viral arteritis with different virus strains
25. Complement-fixation reactions in equine viral arteritis
26. Equine arteritis virus
27. L associated with neutralization resistance
28. Equine arteritis virus: A review of clinical features and management aspects
29. Improved mucosal protection against equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate
30. L, M and N proteins expressed from recombinant baculoviruses
31. The open reading frame 3 of equine arteritis virus encodes an immunogenic glycosylated, integral membrane protein
32. Marburg virus vaccines based upon alphavirus replicons protects guinea pigs and non-human primates
33. Responses of horses vaccinated with avirulent modified-live equine arteritis virus propagated in the E. Derm (NBL-6) cell line to nasal inoculation with virulent virus
34. Resistance of castrated male horses to attempted establishment of the carrier state with equine arteritis virus
35. Studies of an epizootic of equine viral arteritis in race horses
36. The pathogenic qualities of the 1984 strain of equine arteritis virus
37. Experimental observation on the virulence of isolates of equine arteritis virus
38. Response of vaccinated and non-vaccinated mares to artificial insemination with semen from stallions persistently infected with equine arteritis virus
39. Clinical, virological and serological responses of donkeys to intranasal inoculation with the KY-84 strain of equine arteritis virus
40. Analysis of genetic variation among strains of equine arteritis virus
41. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from ebola hemorrhagic fever virus
42. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
43. Venezuelen equine encephalitis viral replicon vector: Immunogenicity studies with ebola NP and GP genes in guinea pigs
44. Alphavirus expression systems-promises and problems
45. The molecular biology of arteriviruses
46. Identification of a novel structural protein of arteriviruses
47. Equine viral arteritis
48. The carrier state in equine arteritis virus infection in the stallion with specific emphasis on the venereal mode of virus transmission
49. Demonstration of the carrier state in naturally acquired equine arteritis virus infection in the stallion